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Abstract
Introduction Although cardiovascular morbidity and mortality
are increased in rheumatoid arthritis, little is known about the
burden of subclinical coronary atherosclerosis in these patients.
Methods Using computed tomography, coronary artery
calcification was measured in 195 men and women with
rheumatoid arthritis aged 45 to 84 years without clinical
cardiovascular disease and compared with 1,073 controls
without rheumatoid arthritis enrolled in the Baltimore cohort of
the Multi-Ethnic Study of Atherosclerosis.
Results The prevalence of coronary calcification (Agatston
score > 0) was significantly higher in men, but not women, with
rheumatoid arthritis after adjusting for sociodemographic and
cardiovascular risk factors (prevalence ratio = 1.19; P = 0.012).
Among participants with prevalent calcification, those with
rheumatoid arthritis had adjusted mean Agatston scores 53
units higher than controls (P = 0.002); a difference greater for
men than women (P for interaction = 0.017). In all analyses,
serum IL-6 attenuated the association between rheumatoid
arthritis and coronary calcification, suggesting its role as a
potential mediator of enhanced atherosclerosis. Notably,
increasing severity of rheumatoid arthritis was associated with a
higher prevalence and extent of coronary calcification among
both men and women with rheumatoid arthritis, and for all age
categories. The largest percentage difference in coronary
arterial calcification between rheumatoid arthritis patients and
their nonrheumatoid arthritis counterparts was observed in the
youngest age category.
Conclusions Increasing rheumatoid arthritis disease severity
was associated with a higher prevalence and greater extent of
coronary artery calcification, potentially mediated through an
atherogenic effect of chronic systemic inflammation. Gender
and age differences in association with coronary calcification
suggest that preventive measures should be emphasized in men
with rheumatoid arthritis, and considered even in younger
rheumatoid arthritis patients with low levels of traditional
cardiovascular risk factors.
Introduction
Cardiovascular disease (CVD) is the leading cause of prema-
ture mortality in rheumatoid arthritis (RA) patients [1,2].
Although several studies have suggested that atherosclerosis
is increased in RA [3,4], few studies have investigated
patients' coronary arteries [5-7]. Coronary arterial calcification
(CAC), a subclinical measure of atherosclerosis measured by
computed tomography (CT), is associated with the degree of
atherosclerotic plaque [8], and is strongly predictive of cardi-
ovascular (CV) events, including those at low risk [9,10]. This
CAC: coronary artery calcification; CRP: C-reactive protein; CT: computed tomography; CV: cardiovascular; CVD: cardiovascular disease; DMARD: 
disease-modifying antirheumatic drug; ELISA: enzyme-linked immunosorbent assay; ESCAPE RA: Evaluation of Subclinical Cardiovascular disease 
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is relevant to RA, as most studies have not shown differences
in traditional CV risk factors between RA patients and controls
[11,12].
Chronic systemic inflammation has been implicated in athero-
genesis, and may play a role in destabilizing vulnerable coro-
nary plaques, thereby precipitating acute thrombosis and
clinical CV events [13]. Interestingly, atherosclerotic plaque
and rheumatoid synovium share an array of inflammatory cells
and cytokines [14], suggesting that chronic rheumatoid inflam-
mation may contribute to excess atherosclerosis in RA. In addi-
tion, RA may modify the atherogenic effects of
noninflammatory risk factors [15], which could explain the
higher atherosclerosis risk of RA patients even when their risk
factor distributions are the same as those of normal controls.
In particular, increasing age and male gender are two of the
strongest predictors of CAC [16], yet no previous studies
have explored their interactions with RA with regard to CAC.
We designed a comparative cohort study of subclinical
atherosclerosis in RA using the Multi-Ethnic Study of Athero-
sclerosis (MESA) [17] cohort as a control group. This study
provided an opportunity to cross-sectionally compare the
presence and extent of CAC between RA patients and a sub-
set of the MESA cohort from the same geographic area utiliz-
ing the same equipment, laboratories and core reading
facilities. We hypothesized that, compared with controls, RA
status in general – and increasing RA severity in particular –
would be associated with a higher CAC prevalence and
extent, and that systemic inflammation would partially account
for these associations. We also explored whether differences
in CAC between RA and control groups varied by gender, age,
and level of RA severity.
Materials and methods
Participants and enrollment
Rheumatoid arthritis subjects
The Evaluation of Subclinical Cardiovascular disease And Pre-
dictors of Events in Rheumatoid Arthritis Study (ESCAPE RA)
is a cohort study of the prevalence, progression, and risk fac-
tors for subclinical CVD in men and women with RA. The
ESCAPE RA study was designed with identical inclusion and
exclusion criteria (except for the diagnosis of RA) to MESA, a
population-based cohort study of subclinical CVD with similar
objectives. The ESCAPE RA inclusion criteria were: fulfillment
of American College of Rheumatology criteria for the classifi-
cation of RA [18] of  6 months; and age 45 to 84 years. Med-
ical records were reviewed for each participant to confirm
diagnosis. Exclusion criteria were: prevalent CVD prior to
enrollment (prior CVD was defined as self-reported or physi-
cian-diagnosed myocardial infarction, heart failure, coronary
artery revascularization, angioplasty, peripheral vascular dis-
ease or procedures (excluding varicose vein procedures),
implanted pacemaker or defibrillator devices, and current atrial
fibrillation); weight exceeding 300 pounds (due to imaging
equipment limitations); and CT scan of the chest within 6
months prior to enrollment (to limit radiation exposure).
Given the greater prevalence of RA in women, we set a recruit-
ment goal of at least 40% males to enable gender-specific
analyses, and recruited 195 patients from the Johns Hopkins
Arthritis Center and by referral from community
rheumatologists.
The study was approved by the Johns Hopkins Hospital Insti-
tutional Review Board and MESA, with all participants provid-
ing informed consent prior to enrollment. Enrollment occurred
from October 2004 through May 2006.
Control subjects
Non-RA controls were Baltimore MESA study participants. A
description of the MESA study design and methods has been
published [17]. In brief, MESA enrolled a multi-ethnic cohort of
6,814 participants from six US communities between 2000
and 2002, among whom 1,086 were enrolled by the Johns
Hopkins (Baltimore) Field Center. Thirteen controls were
excluded for reporting use of disease-modifying antirheumatic
drugs (DMARDs) typically used for the treatment of RA.
Measurement of coronary arterial calcification
All subjects underwent cardiac multidetector row CT scanning
using methodology described previously [19]. CAC was quan-
tified using the Agatston method [20], with a phantom of
known calcium density scanned along with the participant to
ensure standardization across scans [21]. Scans were trans-
mitted electronically to the MESA CT reading center for inter-
pretation. Intra-observer agreement and inter-observer
agreement for CT assessors were high ( = 0.93 and  =
0.90, respectively).
Covariate assessment
The ESCAPE RA study used the same questionnaires, equip-
ment, methods, and quality control procedures as MESA.
Study coordinators were trained and certified by MESA train-
ers. Information on demographics, smoking, and family history
was collected by questionnaire. Resting blood pressure was
measured three times in the seated position, and the average
of the last two measurements was used in the analysis. Hyper-
tension was defined by systolic blood pressure  140 mmHg,
diastolic blood pressure  90 mmHg, or antihypertensive med-
ication use. Diabetes was defined as a fasting serum glucose
 126 mg/dl or use of antidiabetic medications. Physical activ-
ity was assessed using the 7-Day Physical Activity Recall
questionnaire [22]. The body mass index was calculated as
weight (kg) divided by height-squared (m2). Waist and hip cir-
cumferences were measured with a Gulick II anthropometric
measuring tape. Prescription and over-the-counter medica-
tions used in the preceding 2 weeks were documented from
containers supplied by the participant. Composite CV risk
measures were calculated using published criteria for theAvailable online http://arthritis-research.com/content/11/2/R36
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metabolic syndrome (Adult Treatment Panel III) [23], the Fram-
ingham hard 10-year CV risk (National Cholesterol Education
Program) [24], and the Reynolds Risk Score (women only)
[25].
RA-specific covariates
In RA patients, 44 joints were examined by a single trained
assessor for swelling, tenderness, deformity, and surgical
replacement or fusion. RA disease duration was calculated
based on self-report from the time of physician diagnosis. RA
activity was calculated using the Disease Activity Score for 28
joints with C-reactive protein (CRP) [26]. Functional limitation
was assessed with the Stanford Health Assessment Ques-
tionnaire [27]. Current and past use of glucocorticoids and of
biologic and nonbiologic DMARDs was ascertained by inter-
view. Single-view, anterior–posterior radiographs of the hands
and feet were obtained and scored using the Sharp–van der
Heijde method [28] by a single, trained radiologist blinded to
patient characteristics. For five subjects with incomplete radi-
ographic assessments, the missing score (hand or foot) was
imputed from the available data based on a regression equa-
tion using data from the remaining subjects in the cohort.
Laboratory covariates
Fasting sera and plasma were separated by centrifugation,
and were stored at -70°C. All assays (except RA autoantibod-
ies) were performed at MESA-designated laboratories using
MESA quality control procedures. CRP, IL-6, fibrinogen,
homocysteine, soluble intracellular adhesion molecule 1 and
E-selectin were measured as previously described [29]. Low-
density lipoprotein-cholesterol was estimated in plasma spec-
imens having a triglyceride value < 400 mg/dl using the
Friedewald equation. Rheumatoid factor was assessed by
ELISA, with seropositivity defined at or above a level of 40
units. Anti-cyclic citrullinated peptide antibody was assessed
by ELISA, with seropositivity defined at or above a level of 60
units.
Statistical analysis
All participants with interpretable multidetector row CT scans
were included. Means and standard deviations were calcu-
lated for normally distributed variables, and medians and inter-
quartile ranges were calculated for non-normally distributed
variables. Counts and percentages were calculated for cate-
gorical variables. Differences in continuous variables between
the RA and control groups were compared using t tests (for
normally distributed variables) or the Kruskal–Wallis test (for
non-normally distributed variables). Categorical variables were
compared using the chi-square goodness of fit test or Fisher's
exact test. Multivariable linear regression models adjusting for
age, gender, and race/ethnicity were constructed to estimate
adjusted means, 95% confidence intervals, and P values for
CV risk factors.
CAC presence was defined as any detectable coronary cal-
cium (Agatston score > 0). Using an alternative cutoff point of
10 Agatston units did not qualitatively change any of the asso-
ciations observed compared with the 0 unit cutoff point. Multi-
variate analyses were conducted in participants with complete
clinical data (n = 1,222). Poisson regression with robust vari-
ance estimation was used to model the association of RA sta-
tus with the presence of CAC, with prevalence ratios and 95%
confidence intervals calculated. Poisson regression was used
rather than logistic regression since odds ratios would not
approximate prevalence ratios when the outcome is as com-
mon as CAC > 0 in the present study (approximately 50%).
Risk factors considered included age, gender, race/ethnic
background, highest education level attained, systolic and
diastolic blood pressures (or presence of hypertension), anti-
hypertensive medication use, high-density lipoprotein and low-
density lipoprotein, ever smoking, diabetes, lipid-lowering
medication use, fibrinogen, soluble intracellular adhesion mol-
ecule, E-selectin, glucose, amount of weekly intentional exer-
cise, and body mass index or waist circumference. Highly
skewed variables (for example, triglycerides, fibrinogen) were
logarithmically transformed.
Stratified analyses were conducted according to RA severity.
We ranked RA patients using propensity scores [30] for cur-
rent RA disease activity and severity using a model that
included the total Sharp–van der Heijde radiographic score,
the number of swollen and tender joints, the health assess-
ment questionnaire, minutes of morning stiffness, the cumula-
tive prednisone dose, and the number of past DMARDs
prescribed. This method allows each RA subject to be ranked
in order from lowest to highest based on the aggregate of their
predictor variables. Subjects were then grouped into four ordi-
nal categories: MESA control (no RA severity), and RA low
severity, intermediate severity, and high severity based on ter-
tiles of propensity for RA activity and severity. Statistical com-
parisons of differences in the association of RA status with
CAC across subgroups were conducted using the Wald test.
Robust (resistant) regression was used to model the associa-
tion of RA status with the extent of CAC (as a continuous var-
iable) in patients with CAC > 0, with regression coefficients (
values) and 95% confidence intervals calculated. This method
produced estimates similar (to within 1%) to those obtained by
linear regression with logarithmically transformed CAC scores
and exclusion of extreme outliers (falling above and below two
standard deviations of studentized residuals) (data not
shown). Robust regression was preferred as it permitted effi-
ciency in the modeling of all data points in subjects with any
CAC and yielded meaningful results expressed as absolute
means, rather than less meaningful logarithmic means.
Statistical calculations were performed using Intercooled
Stata 9 (StataCorp, College Station, TX, USA). In all tests, aArthritis Research & Therapy    Vol 11 No 2    Giles et al.
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two-tailed  value of 0.05 was defined as the level of statistical
significance.
Results
One-hundred and ninety-five RA patients and 1,073 MESA
controls underwent multidetector row CT scanning. RA
patients tended to have disease of extended duration (median,
9 years), and most (78%) were seropositive for either rheuma-
toid factor or anti-cyclic citrullinated peptide antibodies and,
on average, had evidence of radiographic erosions and
deforming arthropathy (Table 1). RA disease activity was low
to moderate in most patients. The majority of patients (93%)
were treated with DMARDs, including 46% with biologics,
either as monotherapy or in combination with a nonbiologic
DMARD(s); 40% were currently treated with glucocorticoids,
and nearly two-thirds with nonsteroidal anti-inflammatory
drugs.
In unadjusted comparisons (Table 2), the RA group was
younger and included a higher proportion of women and Cau-
casians than controls. The RA group also differed significantly
from the MESA group in many CV risk factors, including a
lower proportion of subjects with diabetes, lower mean fasting
glucose, lower prevalence of hypertension despite higher
mean diastolic blood pressure, and higher mean high-density
lipoprotein-cholesterol concentration. As expected, RA
patients had significantly higher median CRP, IL-6, and soluble
intracellular adhesion molecule levels than MESA participants.
Among composite risk measures, the RA group had a signifi-
cantly lower mean Framingham 10-year hard CV risk score,
lower mean Reynolds Risk Score, and lower proportion of
patients who met the Adult Treatment Panel III criteria for met-
abolic syndrome [23].
Owing to imbalances in demographic characteristics between
groups, mean CV risk factor levels by RA status were adjusted
for age, gender, and race/ethnicity (Table 2). Thereafter, com-
pared with controls, RA patients had significantly higher
adjusted mean systolic and diastolic blood pressures, high-
density lipoprotein-cholesterol, homocysteine, fibrinogen, and
Table 1
Baseline disease-related characteristics of rheumatoid arthritis patients: the ESCAPE RA study
Characteristic Tertiles of propensity for rheumatoid arthritis activity and severity
All (n = 195) Tertile 1 (lowest, n = 65) Tertile 2 (middle, n = 65) Tertile 3 (highest, n = 65) P value
Disease characteristics
Disease duration (years) 9 (4 to 17) 4 (2 to 6) 8 (5 to 13) 21 (16 to 31) <0.001
Rheumatoid factor or anti-
cyclic citrullinated peptide 
seropositivity
152 (78.0) 37 (57.8) 58 (89.2) 53 (86.9) <0.001
Disease Activity Score (for 
28 joints – C-reactive 
protein)
3.57 (2.87 to 4.35) 3.18 (2.54 to 3.99) 3.57 (2.87 to 4.29) 4.00 (3.35 to 4.88) <0.001
Health assessment 
questionnaire score (0 to 3)
0.63 (0.13 to 1.25) 0.13 (0 to 0.50) 0.75 (0.13 to 1.25) 1.38 (1.00 to 1.88) <0.001
Total Sharp–van der Heijde 
Score
44 (16 to 116) 18 (5 to 36) 38 (20 to 68) 142 (83 to 221) <0.001
Deformed + replaced joints 2 (0 to 7) 1 (0 to 2) 1 (0 to 3) 10 (4 to 14) <0.001
C-reactive protein (mg/l) 2.46 (1.09 to 7.17) 1.7 (0.78 to 4.56) 2.6 (1.18 to 7.80) 2.96 (1.66 to 9.46) 0.004
Current treatment
Nonbiologic DMARDs only 94 (48.2) 37 (57.8) 29 (44.6) 25 (41.0) 0.19
Biologic DMARD 
monotherapy
19 (9.7) 5 (7.8) 3 (4.6) 10 (16.4)
Nonbiologic + biologic 
DMARDs
70 (35.9) 20 (31.3) 28 (43.1) 22 (36.1)
No DMARDs 12 (6.2) 2 (3.1) 5 (7.7) 4 (6.6)
Glucocorticoids 75 (38.5) 23 (35.9) 20 (30.8) 31 (50.8) 0.06
Nonsteroidal anti-
inflammatory drugsa
126 (64.6) 40 (61.5) 41 (63.1) 45 (69.4) 0.67
Characteristics expressed as median (interquartile range) or n (%). DMARD, disease-modifying antirheumatic drug; ESCAPE RA, Evaluation of 
Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis. aIncludes both cyclooxygenase-2 selective and nonselective 
nonsteroidal anti-inflammatory drugs.Available online http://arthritis-research.com/content/11/2/R36
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Table 2
Crude and adjusted baseline characteristics of rheumatoid arthritis patients and controlsa
Unadjusted Adjusted
RA (n = 195) MESA (n = 1,073) P value RA (n = 195) MESA (n = 1,073) Adjusted % difference P value
Demographics
Age (years) 59 ± 9 64 ± 10 <0.001 - - - -
Female 118 (60.5) 526 (49.0) 0.003 - - - -
Race
Caucasian 169 (85.8) 540 (50.3) <0.001 - - - -
African 
American
16 (8.2) 533 (49.7)
Other 10 (5.1) 0 (0)
Education
Some college or 
higher
147 (75.4) 741 (71.5) 0.26 69.9 73.6 -5.0 0.34
Cardiovascular risk 
factors
Diabetes 11 (5.6) 142 (13.2) 0.003 8.1 11.1 -27.0 0.29
Fasting glucose 
(mg/dl)
93 ± 21 105 ± 31 <0.001 95.9 103.8 -8.2 0.001
Hypertension
Presentb 105 (53.6) 597 (55.6) 0.59 64.3 54.3 +18.4 0.018
Systolic blood 
pressure 
(mmHg)
128 ± 19 128 ± 21 0.93 132 125 +5.6 0.002
Diastolic blood 
pressure 
(mmHg)
76 ± 9 72 ± 10 <0.001 77.1 71.5 +7.8 <0.001
Antihypertensive 
use
79 (40.5) 428 (39.9) 0.87 53.0 36.4 +45.6 <0.001
Lipids
Total cholesterol 
(mg/dl)
195 ± 38 197 ± 38 0.62 194 197 -1.5 0.41
LDL cholesterol 
(mg/dl)
116 ± 31 117 ± 32 0.53 115.2 117.6 -2.1 0.34
HDL cholesterol 
(mg/dl)
55 ± 19 52 ± 15 0.03 54.4 51.6 +5.4 0.020
Triglycerides 
(mg/dl)
126 ± 93 118 ± 72 0.25 101.2 103.8 -2.5 0.53
Lipid medication 
use
34 (17.4) 231 (21.5) 0.20 16.2 21.6 -25.0 0.10
Cigarette smoking
Current 23 (11.8) 152 (14.4) 0.33 10.1 12.9 -21.7 0.30
Ever 115 (59.0) 591 (56.9) 0.60 59.2 57.4 +3.1 0.67
Body mass index 
(kg/m2)
28.4 ± 5.3 29.3 ± 5.7 0.034 28.8 29.3 -1.7 0.25
Waist 
circumference (cm)
95.7 ± 15.5 99.5 ± 14.7 0.002 96.9 99.3 -2.4 0.050
Any physical activity 144 (73.9)) 832 (78.5 0.15 70.6 80.0 -11.8 0.010Arthritis Research & Therapy    Vol 11 No 2    Giles et al.
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significantly lower fasting glucose, with percentage differ-
ences ranging from -8.2% (fasting glucose) to +7.8% (diasto-
lic blood pressure). Adjusted mean CRP and IL-6
concentrations were 44% and 208% higher, respectively, in
RA patients than controls. After adjustment, Framingham 10-
year hard CV risk scores were significantly higher in the RA
group by an average of 1.1 percentage points, while the mean
Reynolds Risk Score (women only) did not significantly differ
according to RA status.
Association of RA status with the presence and extent of 
coronary arterial calcification
In crude comparisons, the prevalence of any CAC did not dif-
fer between the RA and MESA groups (55% vs. 56%, respec-
tively). After sociodemographic and risk factor adjustment
(Table 3, model 3), however, CAC prevalence was slightly
higher in the RA group (prevalence ratio = 1.12; 0.05 < P <
0.10); this association was no longer present when IL-6 was
entered into the model (Table 3, model 4). Stratification by
gender revealed a significantly higher CAC prevalence in RA
men after adjustment, but not in women, than in their controls
– a heterogeneity that was statistically significant (P for inter-
action = 0.032). The heterogeneity was no longer significant
after adjustment for IL-6 (Table 3, model 4).
In participants with prevalent CAC (Agatston score > 0), the
CAC extent was significantly associated with increasing age,
male gender, non-African American race, hypertension, diabe-
tes, ever smoking, low-density lipoprotein-cholesterol, and RA
status in multivariable analyses (data not shown). After adjust-
ment for these demographic and CV risk factors, the mean
adjusted CAC score (in those with an Agatston score > 0)
was 53 units higher in the RA group overall compared with
non-RA controls (Table 4, model 3; P = 0.002). Adding IL-6
into the model as a potential mediator attenuated this differ-
ence by an average of 10 units (18%) that, however, remained
statistically significant (P = 0.028). Similar attenuation was
observed when CRP was modeled as a potential mediator
(data not shown). Differences in adjusted mean CAC scores
were greater for men than for women with RA vis-à-vis their
controls (Figure 1a; P for interaction = 0.017).
Differences in mean Agatston scores by RA status were also
heterogeneous by age category (Figure 1b). Significantly
higher adjusted mean Agatston scores were observed for RA
patients compared with controls in the youngest (45 to 54
years) and oldest (65+ years) age groups, but not in the mid-
dle age group (55 to 64 years) (P value for age group interac-
tion comparing the youngest or oldest age group with the
middle age group < 0.05 for both). The greatest percentage
difference in mean adjusted Agatston scores between RA
Homocysteine 
(mol/l)
9.45 ± 2.80 9.28 ± 3.23 0.45 9.49 8.88 +6.9 0.003
Serum inflammatory 
markers
C-reactive 
protein (mg/l)
2.5 (1.1 to 7.2) 2.2 (1.0 to 4.7) 0.03 3.0 2.1 +44.0 <0.001
IL-6 (pg/ml) 3.9 (1.8 to 7.8) 1.3 (0.8 to 2.0) <0.001 4.0 1.3 +208 <0.001
Fibrinogen (mg/
dl)
335(278 to 416) 340 (294 to 390) 0.98 358 338 +5.9 0.001
sICAM-1 (ng/ml) 299(229 to 371) 261 (219 to 307) <0.001 293 259 +13.1 <0.001
E-selectin (ng/
ml)
49 (30 to 73) 50 (40 to 63) 0.46 50 49 +1.4 0.85
Composite risk factors
Framingham 10-
year riskc (%)
7 ± 7 8 ± 7 0.04 9.35 8.25 +13.3 0.006
Reynolds Risk 
Score (women 
only) (%)
1.0 (0 to 2.0) 1.4 (0.2 to 2.7) 0.001 1.50 1.42 +5.6 0.60
Metabolic 
syndrome (Adult 
Treatment Panel III)
44 (22.6) 368 (34.5) <0.001 24.4 34.0 -28.2 0.016
aEvaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis (ESCAPE RA) study. Adjusted for age, gender 
and race. Characteristics expressed as the mean ± standard deviation, as n (%) or as the median (interquartile range). HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; MESA. Multi-Ethnic Study of Atherosclerosis; RA. rheumatoid arthritis; sICAM-1, soluble intracellular 
adhesion molecule 1. bPresence of hypertension defined as resting blood pressure >140/90 mmHg or use of antihypertensive medication. 
cNational Cholesterol Education Program criteria; excluding diabetics (fasting glucose  126 or use of diabetes medication).
Table 2 (Continued)
Crude and adjusted baseline characteristics of rheumatoid arthritis patients and controlsaAvailable online http://arthritis-research.com/content/11/2/R36
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patients and controls was observed in the youngest age
group, in which Agatston scores were 2.5-fold higher for RA
patients.
Association of RA severity with the presence and extent 
of coronary arterial calcification
The CAC prevalence increased as the propensity scores for
RA disease activity and severity increased (Figure 2). After
adjusting for sociodemographics and CV risk factors, the prev-
alence of any CAC for RA patients in the lowest tertile of RA
severity did not significantly differ from that of MESA controls
(48% vs. 49.4%, respectively); however, the adjusted CAC
prevalence was 61.4% in RA patients in the highest tertile of
RA severity, a difference that was statistically significant com-
pared with MESA controls (P = 0.021). Notably, the trend of
increasing prevalence of any CAC with increasing RA severity
was observed for both men and women with RA.
Increasing RA severity was associated with higher mean CAC
scores in participants with prevalent CAC (Agatston score >
0), such that the difference in adjusted mean CAC scores
between the lowest RA severity tertile and controls was small
and nonsignificant, but the difference was large and significant
between the middle–upper severity tertiles and MESA con-
trols (Figure 3a). For example, RA patients in the highest tertile
of RA severity had an adjusted Agatston score of 202 versus
only 121 in controls (P = 0.006). This pattern was seen in both
genders (Figure 3a) and across all age groups (Figure 3b). No
statistically significant interactions were seen between RA
severity and gender or age.
Discussion
In the present study – the largest study to date investigating
Table 3
Crude and adjusted prevalence ratios for any coronary calcification (Agatston score > 0)a
RA vs. non-RA Model 1 Model 2 Model 3b Model 4
Total participants 0.98 (0.85 to 1.13) 1.08 (0.95 to 1.23) 1.12 (0.99 to 1.27) 1.00 (0.86 to 1.17)
Men only 1.15 (1.00 to 1.33) 1.16*(1.01 to 1.33) 1.19* (1.04 to 1.29) 1.14 (0.96 to 1.36)
Women only 0.87 (0.69 to 1.10) 1.06 (0.85 to 1.32) 1.09 (0.87 to 1.36) 0.89 (0.69 to 1.16)
aPrevalence ratios (95% confidence intervals) for rheumatoid arthritis (RA) participants and controls in the Evaluation of Subclinical 
Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis study. Prevalence ratios indicate the ratio of the prevalence of coronary 
artery calcification > 0 for RA participants compared with Multi-Ethnic Study of Atherosclerosis controls. Analyses include 1,222 subjects with 
complete data (RA, n = 193; control, n = 1,029). Model 1, crude model, no adjustment; model 2, adjusted for demographics (age, gender (where 
appropriate), race, and highest educational level attained); model 3, adjusted for model 2 covariates + cardiovascular risk factors (hypertension, 
high-density lipoprotein-cholesterol and low-density lipoprotein-cholesterol, diabetes, ever smoking, and use of lipid-lowering medication); model 
4, adjusted for model 3 covariates + log IL-6. bAdditional covariates tested but noncontributory to the model: log CRP, log fibrinogen, log soluble 
intracellular adhesion molecule, triglycerides, exercise, body mass index, and waist circumference. *P value for the gender interaction significant at 
< 0.05.
Table 4
Crude and adjusted associations of rheumatoid arthritis status with mean Agatston scoresa
M o d e l  1M o d e l  2M o d e l  3M o d e l  4 b
Characteristic  (95% CI)  (95% CI)  (95% CI)  (95% CI)
RA vs. MESAc 32.6* (2.04 to 64.1) 44.4* (12.3 to 76.4) 53.1* (19.8 to 86.4) 43.8* (4.9 to 82.8)
Crude
Mean (95% CI)
Adjusted
Mean (95% CI)
Adjusted
Mean (95% CI)
Adjusted
Mean (95% CI)
RA CAC scored 145 (116 to 174) 162 (133 to 191) 175 (144 to 205) 166 (131 to 200)
MESA CAC scored 112 (100 to 125) 118 (105 to 130) 122 (109 to 134) 122 (109 to 135)
aAssociations in subjects with prevalent coronary calcification in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in 
Rheumatoid Arthritis study. Analyses include 667 subjects with Agatston coronary artery calcification (CAC) score > 0 and complete data. Model 
1, crude model, no adjustment; model 2, adjusted for sociodemographics (age, gender, African American race, highest educational level attained); 
model 3, adjusted for model 2 covariates + cardiovascular risk factors (hypertension, diabetes, smoking, high-density lipoprotein-cholesterol and 
low-density lipoprotein-cholesterol, and lipid lowering medication use); model 4, adjusted for model 3 covariates + log IL-6. bAdditional covariates 
tested but noncontributory to the model: log C-reactive protein, log fibrinogen, log soluble intracellular adhesion molecule, log homocysteine, 
exercise, body mass index, and waist circumference. c  coefficients (95% confidence intervals) representing the difference in mean Agatston 
CAC score for rheumatoid arthritis (RA) participants vs. Multi-Ethnic Study of Atherosclerosis (MESA) controls from robust regression models. *  
coefficient significant at P < 0.05.dValues represent crude (model 1) and adjusted (models 2 to 4) mean (95% confidence interval) coronary artery 
calcification scores per group (RA or MESA) under the robust regression model above.Arthritis Research & Therapy    Vol 11 No 2    Giles et al.
Page 8 of 12
(page number not for citation purposes)
AC in RA – we observed a higher prevalence and extent of
CAC in RA patients compared with a geographically compat-
ible population of non-RA controls after CV risk and sociode-
mographic adjustments. These associations were attenuated
to varying degrees in models including IL-6, a marker of system
inflammation – suggesting that IL-6 is a potential mediating
variable. Increasing overall RA severity was also associated
with a higher prevalence and extent of CAC, further suggest-
ing that the RA disease process contributes to atherogenesis
independently of traditional CV risk factors. We also observed
age and gender heterogeneities with potential implications for
RA patients. In particular, differences in CAC between men
Figure 1
Adjusted mean Agatston calcium scores for participants with any coronary artery calcification (Agatston score > 0) Adjusted mean Agatston calcium scores for participants with any coronary artery calcification (Agatston score > 0). Adjusted mean Agatston cal-
cium scores for participants with any coronary artery calcification according to rheumatoid arthritis (RA) status and (a) gender and (b) age category. 
Analyses include 667 subjects with complete data. Analyses were adjusted for age, gender (where appropriate), race, hypertension, high-density 
lipoprotein-cholesterol and low-density lipoprotein-cholesterol, diabetes, ever smoking, and use of lipid-lowering medication. Means are enumerated 
and 95% confidence intervals (CIs) are indicated. P for gender interaction = 0.017; P < 0.05 for both age group interaction comparing the youngest 
or oldest age group with the middle age group.Available online http://arthritis-research.com/content/11/2/R36
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with RA and male controls were greater than those for women.
In addition, the largest percentage difference in CAC between
RA patients and their non-RA counterparts was observed in
the youngest age category.
Two previous studies explored CAC in RA [5,6]. Chung and
colleagues investigated whether RA duration was associated
with a higher CAC prevalence by enrolling only patients with
either early RA (RA duration <5 years) or established RA (RA
duration > 10 years), and compared these groups with a small
group of non-RA controls [5]. A greater prevalence of CAC
was observed in the established RA group compared with
both the control and early RA groups after adjusting for demo-
graphic and current CV risk factors. Their study did not, how-
ever, include a sufficient sample of men to analyze this group
separately. In the study by Kao and colleagues, an association
between the RA duration and the extent of CAC was
observed, independently of demographic and CV risk factors
[6]. Their study did not incorporate a non-RA comparison
group, however, and only women were enrolled. The present
report differs from these prior studies in several important
ways. The current study's larger size and comparison with
MESA allowed subgroup comparisons by gender and age cat-
egory that revealed potentially important heterogeneities. In
addition, our exclusion of prior CV events allowed a focus on
subclinical disease, thus limiting potential skewing of CAC in
groups with prior CV events and procedures.
The mechanism underlying the observed increase in CAC in
RA is likely complex and multifactorial. In multiple population-
based studies [31-33], individuals with the highest concentra-
tions of circulating inflammatory markers were at greatest risk
for CV events and mortality, and tended to demonstrate an
increased burden of subclinical atherosclerosis, including CT-
measured CAC [34]. A direct effect of inflammatory cytokines
on the vasculature in promoting atherogenesis and destabiliz-
ing coronary plaques has been proposed as a potential mech-
anism [13]. RA patients have considerably higher circulating
levels of inflammatory cytokines than non-RA controls, and
adjustment for IL-6 in the statistical models partially attenuated
the observed association between RA status and CAC, sug-
gesting that systemic inflammation accounted for at least part
of the association. We did not, however, see the same magni-
tude of attenuation upon adjustment for serum CRP concen-
tration, which has been associated with CV events and
subclinical atherosclerosis [31,34]. While this apparent dis-
connection might suggest pathogenic specificity of individual
inflammatory cytokines, these speculations are limited by the
cross-sectional nature of the analysis, and the discrepancy
may be the result of random variability. Importantly, a single
measurement of inflammatory cytokines is not representative
of the total inflammatory burden of RA patients. While follow-
up will help to assess the associations of cumulative inflamma-
tion with progression of CAC in RA patients, the cross-sec-
tional association of RA propensity scores (a clinical reflection
of current and past burden of disease) with CAC nonetheless
supports an association between inflammation and CAC. On
the other hand, finding that the association of RA status and
CAC is only partially attenuated by IL-6 suggests the presence
of additional RA-related mediators. These might include a phe-
notypically unusual T-cell clone (CD4+CD28-) [35], shared
risk factors (such as genetic predisposition), RA treatments
(such as glucocorticoids and nonsteroidal anti-inflammatory
drugs), and the debilitating effect of joint pain and stiffness on
physical activity and fitness.
In most studies of CVD in RA, differences in the prevalence of
traditional CV risk factors compared with controls have not
been detected [11,12]. We detected small but significant dif-
ferences in blood pressure in RA patients compared with con-
trols that could affect CV risk unfavorably. We also detected
higher mean high-density lipoprotein-cholesterol, lower mean
fasting glucose and diagnosed diabetes, and lower preva-
lence of the metabolic syndrome in the RA groups, however –
all of which could decrease CV risk. Although heterogeneity in
the associations with traditional CV risk factors, other than age
and gender, on CAC by RA status was not explored, our find-
ings suggest that conventional means of risk-stratifying RA
patients probably underestimate their risk. In particular, the
largest difference in CAC, by a several-fold increase, between
RA patients and controls was observed in the youngest age
category, an age group in which CAC is typically low in both
men and women [16]. This same heterogeneity by age has
also been observed for carotid plaque in a study primarily of
women with RA [4], in which the largest percentage difference
Figure 2
Adjusted associations of rheumatoid arthritis severity with prevalence  of coronary artery calcification (Agatston score > 0) Adjusted associations of rheumatoid arthritis severity with prevalence 
of coronary artery calcification (Agatston score > 0). Tertiles of rheuma-
toid arthritis (RA) severity according to gender are gender-specific. 
Prevalence of any coronary calcium is given as a percentage of the 
total. Adjusted comparisons include age, gender (where appropriate), 
race, highest education level attained, hypertension, high-density lipo-
protein-cholesterol and low-density lipoprotein-cholesterol, diabetes, 
ever smoking, and use of lipid-lowering medication. Analyses include 
1,222 subjects with complete data (RA, n = 193; control, n = 1,029). 
*P < 0.05 compared with the non-RA group. **P < 0.05 compared with 
both the non-RA group and the lowest tertile of RA severity.Arthritis Research & Therapy    Vol 11 No 2    Giles et al.
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in the prevalence of carotid plaque was observed in the RA
patients younger than age 50 years.
There are some notable limitations to our study. As MESA is a
population-based study without exclusion of patients with
rheumatic disease, it is possible that RA patients could have
been included in the non-RA control group. As such potential
misclassification would tend to lessen the observed differ-
ences between the RA and control groups, the true effect of
complete accuracy in the classification of exposure status
would actually strengthen the association of RA status with
CAC. To reduce misclassification by RA status, we excluded
Figure 3
Adjusted mean Agatston scores for participants with coronary artery calcification according to rheumatoid arthritis severity Adjusted mean Agatston scores for participants with coronary artery calcification according to rheumatoid arthritis severity. Adjusted mean Agatston 
calcium scores for participants with any coronary artery calcification (CAC) (Agatston score > 0) according to tertiles of rheumatoid arthritis (RA) 
severity, by (a) gender and (b) age category. Analyses include 667 subjects with complete data. Tertiles of propensity for RA disease activity and 
severity according to age category are gender-specific. Analyses were adjusted for age, race/ethnicity, hypertension, high-density lipoprotein-cho-
lesterol and low-density lipoprotein-cholesterol, diabetes, ever smoking, and use of lipid-lowering medication. Means are enumerated and 95% con-
fidence intervals (CIs) are indicated. P values for the linear trend of increasing RA severity with CAC are < 0.05 for the total group and in all 
subgroup analyses.Available online http://arthritis-research.com/content/11/2/R36
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patients from the control group who reported using medica-
tions commonly used to treat active RA. While this method of
identification of RA is more reliable than patient self-report of
the diagnosis [36] and is commonly used in epidemiological
studies for the diagnosis of RA, there are limitations – RA
patients not taking DMARDs would be included, and those
with other diseases in which these medications are used, such
as Crohn's disease or psoriasis, would be excluded. Another
limitation is that calcification of coronary plaque may not be
equally representative of the same atherosclerotic burden in
RA patients as controls, since noncalcified soft plaque is not
detected by Agatston scoring [37]. This limitation is supported
by a recent autopsy study in which RA patients demonstrated
scattered vulnerable plaques that were highly inflammatory on
histologic examination despite having less extensive athero-
sclerotic burden overall compared with controls [7]. Finally,
differences in referral patterns into the study (community
based for the MESA vs. clinic based for the ESCAPE RA
study) could have introduced selection bias or confounding on
factors not related to exposure status. However, as the two
cohorts were geographically compatible, as all of the ESCAPE
RA patients were community dwelling, and as many ESCAPE
RA patients were recruited from community rheumatologists,
it is likely that any bias related to selection would be limited.
Another potential problem is that the analyses were cross-sec-
tional, and thus temporality cannot be established.
Conclusions
In summary, we observed a greater prevalence and extent of
CAC in RA patients compared with controls even after adjust-
ing for key confounders. In addition, associations were linked
to overall RA severity and were of greater magnitude for men
and younger patients. Interventional trials targeted at tight con-
trol of RA and at aggressive monitoring and management of
CV risk factors are needed to identify the most effective means
of reducing CV risk in this high-risk population.
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